Skip to main content
Reid W. Merryman on Muck Rack

Reid W. Merryman

As seen in: Nature, Wiley, Wiley Online Library, The Lancet, HemOnc Today, Ash Publications, Blood, ONCOLOGY journal, OncLive, Targeted Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Reid W.

Contact Reid W., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin

|
By Shin Yeu Ong, LU CHEN, Jomel Meeko Manzano, Reid W. Merryman, Harsh Shah, Robert Stuver, Sanjal Desai, Ann S. LaCasce, Ayo S Falade, Kelsey Baron, Nivetha Ganesan, Tiffany C. Chang, Urshila Durani, Tamer Othman, Philippe Armand, Matthew Mei, Alison J. Moskowitz, Alex Herrera, Álex Herrera
| Nature Verified
Abstract Frontline therapy for classic Hodgkin Lymphoma (cHL) incorporating brentuximab vedotin (BV) improves outcomes compared with traditional chemotherapy, but up to 20% of patients relapse and need salvage treatment. Prior retrospective studies examining salvage therapies are mostly limited to patients who received chemotherapy-based treatment in frontline without novel agents.
Open in Who Shared Issue with article?

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma Original

|
By Karan L. Chohan, James Godfrey, Lorenzo Falchi, Manali K. Kamdar, Ajay Major, Wendy O. Dixon, Jennifer Crombie, Reid W. Merryman, Gilles Salles, Amy Ayers, Ayushi Chauhan, Alex Herrera, Álex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha, Rina L. Welkie, Steven Bair, Sonia Godbole, Omnia Farahat
| Nature Verified
Dear Editor, Despite recent advances in the treatment of systemic aggressive B-cell non-Hodgkin lymphomas (B-NHL), central nervous system (CNS) involvement remains a therapeutic challenge and is associated with dismal outcomes [1]. Chimeric antigen receptor (CAR) T-cell therapy achieves high overall response rates (ORR) in patients with CNS involvement, but responses are often short-lived (1-year progression-free survival (PFS) of 16–48%) [2,3,4,5].
Open in Who Shared View Duplicates (2) Issue with article?

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

|
By Yucai Wang, Melissa Larson, Steven Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar Verified, Ashlee Joseph, Taylor Brooks, Brian Hill, David Bond, Kami J. Maddocks, Alexey B. Danilov, Jia Ruan, Imran Nizamuddin, Brad S. Kahl, Natalie Grover Verified, Georgios Pongas, Izidore S. Lossos, Evguenia Ouchveridze, Aung M. Tun, Firas Baidoun, Muhamad Alhaj Moustafa, Zoey Harris, Javier Muñoz, Philip Young, Craig Portell, Patrick M Reagan, Christine Ryan, Reid W. Merryman, Arash Velayati, Drew Gerber, Preetesh Jain, Michael Wang, Eric Mou, Lauren G. Banaszak, Priyanka A. Pophali, Anthony Stack, Marcus Messmer, Mayur Narkhede, Amitkumar Mehta, Nilanjan Ghosh, Rahul S Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob L. Anna, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon Cohen, Peter Martin, Christine Argao, Nazneen B. Khan, I. Brian Greenwell, Sabarish R. Ayyappan, Tamara K. Moyo, Alexander V. Stanisic
| Nature Verified
Abstract Addition of Bruton’s tyrosine kinase inhibitor (BTKi) to first-line (1 L) bendamustine-rituximab (BR) improved progression-free survival (PFS) in patients with mantle cell lymphoma (MCL) in the SHINE and ECHO trials. We investigated whether sequential treatment with 1 L BR and second-line (2 L) BTKi can result in similar cumulative PFS compared to BR-BTKi combination therapy, using a multicenter cohort of 755 patients treated with 1 L BR between 2014 and 2020.
Open in Who Shared Issue with article?
See all 17 licensed articles (20 Total)